You are here: Industry Insights > palbociclib

News List

Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors prnasia
June 15, 2021
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the Investigational New Drug (IND) application for the ...
Researchers identify existing drug’s potential for triple negative breast cancer pharmatimes
January 29, 2021
Researchers at The Institute of Cancer Research, London (ICR) have identified an already approved breast cancer drug which could have promise in the treatment of triple negative breast cancer (TNBC).
Pfizer files patent infringement petition in US court against Aurobindo, Dr Reddy’s expresspharma
November 19, 2020
Alleges that these Indian pharma companies were planning separately to come out with generic versions of its cancer drug Ibrance (palbociclib) before the expiration of its patent.
Zydus Cadila receives tentative USFDA approval for palbociclib capsules expresspharma
September 27, 2020
It is an anti-cancer medicine that interferes with the growth and spread of cancer cells in the body.
NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers europeanpharmaceuticalreview
January 16, 2020
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
Blood test predicts effectiveness of palbociclib in breast cancer patients europeanpharmaceuticalreview
April 25, 2019
A new study has found a blood test for cancer DNA could predict if a woman is responding to the new breast cancer drug palbociclib, months earlier than current tests…
Palbociclib improves patients’ survival in metastatic breast cancer europeanpharmaceuticalreview
October 31, 2018
A Phase III clinical trial has shown that a combination of palbociclib and fulvestrant leads to a longer survival for HR-positive breast cancer…
Alliance Foundation Trials opens global trial investigating first-in-class palbociclib in HR+, HER2+ worldpharmanews
August 24, 2017
The Alliance Foundation Trials, LLC， in conjunction with Pfizer and six international cancer research groups, have announced the launch of PATINA - a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/6 inhibitor palbociclib
Pfizer’s breast cancer drug too expensive for NHS europeanpharmaceuticalreview
February 06, 2017
The National Institute for Health and Care Excellence (NICE) has today published draft guidance which does not recommend breast cancer drug palbociclib (Ibrance, Pfizer) for routine funding on the NHS. A full course of treatment costs £79,650.